The Effects of Budesonide Inhalation Treatment on the Expression Levels of Serum IL-6, TGF-β1, and IgE and Pulmonary Function in Patients with Cough Variant Asthma and an Evaluation of Treatment Efficacy
DOI: https://doi.org/10.2147/ijgm.s455872
IF: 2.145
2024-03-30
International Journal of General Medicine
Abstract:Yueying Niu, 1 Mengqing Cao, 1 Shumin Li, 1 Juanfen Mo, 2 Ziyi Zhu, 1 Haiqin Wang 1 1 Department of Respiratory Medicine, The Second Hospital of Jiaxing, Jiaxing, Zhejiang, People's Republic of China; 2 The Key Laboratory, The Second Hospital of Jiaxing, Jiaxing, Zhejiang, People's Republic of China Correspondence: Haiqin Wang; Ziyi Zhu, Department of Respiratory Medicine, The Second Hospital of Jiaxing, 1518 Huanchen North Road, Jiaxing, Zhejiang, 314000, People's Republic of China, Email ; Objective: To retrospectively study the effects of budesonide inhalation combined with conventional symptomatic treatment on serum inflammatory factor expression levels and pulmonary function in patients with cough variant asthma (CVA) and to evaluate treatment efficacy. Methods: This retrospective cohort study included 200 patients diagnosed with CVA at the Second Hospital of Jiaxing between January 2022 and June 2023 and given conventional symptomatic treatment plus budesonide inhalation were included in this study. Patients were divided into a no remission group, a partial remission group and a complete remission group based on treatment effect. The expression levels of serum inflammatory factors, cough symptom scores, and small airway function indicators in the three groups of patients at different time points were compared. Results: In the three groups of CVA patients, after receiving budesonide inhalation combined with conventional symptomatic treatment, the expression levels of serum IL-5, IL-6, IL-8, TNF-α, TGF-β 1, and IgE and number of eosinophils significantly decreased (P < 0.05). There were statistically significant differences in the IL-6 and TGF-β 1 levels among the three groups of CVA patients at T1, T2 and T3. There were statistically significant differences in IgE levels, number of eosinophils, cough symptom scores, and small airway function indicators between T2 and T3 (P< 0.05). The receiver operating characteristic (ROC) curve prediction analysis revealed significant differences in the expression of IL-6 and TGF-β 1 at T1, T2, and T3. Conclusion: Budesonide inhalation combined with conventional symptomatic treatment can significantly reduce the levels of serum inflammatory factors in patients with CVA to reduce inflammation and the allergic response, thereby reducing the cough symptom score, improving pulmonary function, and improving therapeutic efficacy. In addition, IL-6 and TGF-β 1 can be used as early predictors of budesonide inhalation efficacy. Keywords: budesonide, cough variant asthma, cytokines, IL-6, TGF-β 1 Cough variant asthma (CVA) is a type of asthma whose main clinical manifestation is chronic cough accompanied by airway hyperresponsiveness, with no obvious symptoms or signs of wheezing and shortness of breath, 1 and it is more obvious at night or in the early morning. In recent years, due to environmental changes, the overuse of antibiotics and other factors, the incidence of CVA has increased annually. 2,3 The pathogenesis of CVA has still not been fully elucidated. Scholars in China and abroad have proposed that CVA has certain similarities to typical bronchial asthma; that is, chronic inflammatory changes in the airway are predominantly caused by eosinophilic infiltration, with the participation of a variety of inflammatory cells and mediators, and airway hyperresponsiveness. 4,5 Moreover, eosinophils can produce leukotriene mediators, thus causing inflammation. 6 Moreover, simple and effective monitoring and evaluation measures for the treatment response and prognosis of patients with CVA are lacking. If CVA cannot be effectively controlled in a timely manner, it may develop into typical asthma. At present, the "Guidelines for the Diagnosis and Treatment of Cough" in China recommend glucocorticoids combined with conventional treatment for CVA, and the clinical benefits have been significant. Due to the differences between individual patients and variations in conditions, the treatment response of patients still needs to be evaluated in a timely manner during clinical treatment to rationally adjust regimens. 7 Routine treatments for CVA include bronchodilators, glucocorticoids, antiallergic drugs, and leukotriene receptor antagonists. 8,9 Budesonide is a glucocorticoid, and its unique molecular structure leads to long-acting, highly effective, and local anti-inflammatory effects. 10 It has a clear first-pass effect and can reduce inflammatory damage, control airway sensitivity, improve pulmonary function, and reduce the symptoms of asthma; therefore, it is often used in nebulized inhalation. 11 The commonly used clinical methods f -Abstract Truncated-
medicine, general & internal